Tag: coronavirus
Lessons Learned From the First 50 COVID-19 Critical Care Transfer Missions
Critically ill COVID-19 patients have highly complex medical needs during transport. Critical care transfer of COVID-19-positive patients by civilian HEMS services, including air transfer, can be achieved safely with specific... read more
The Value of Echocardiography Combined with Lung Ultrasound to Evaluate COVID-19 Pneumonia
In COVID-19 pneumonia patients, the pulmonary arterial pressure and LUS are positively correlated. For those who are unable to be transferred or relocated, the pulmonary arterial pressure may be measured to reflect the degree... read more
High-Dose Dexamethasone vs. Tocilizumab in COVID-19 Pneumonia
Our study findings discourage the use of high doses of dexamethasone in the management of moderate to severe COVID-19 ARDS. The routine use of such high doses to mitigate the inflammatory cytokine storm in these patients... read more
Recognizing Vaccine-Induced Immune Thrombotic Thrombocytopenia
Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs,... read more
New Resuscitation Guidance for Patients with COVID-19
In response to the COVID-19 pandemic, the American Heart Association and collaborating organizations, including the American Academy of Pediatrics, the American Association for Respiratory Care, the Society of Critical Care... read more
Inhaled Corticosteroid Use on COVID-19 Outcomes Among Hospitalized Adult Asthmatics
While our findings confirm trends observed by others with respect to risk factors among asthmatics with COVID-19, differences based on sex, ethnicity and ICS use in asthmatics were observed. Our finding that ICS use was associated... read more
The Role of Antiviral Treatment in the COVID-19 Pandemic
US Food and Drug Administration (FDA) issued an emergency use authorisation for Pfizer's COVID-19 antiviral, Paxlovid few weeks ago. Trial results released by the manufacturer indicate that the drug cuts the risk of hospitalisation... read more
Noninvasive Respiratory Support for COVID-19 Patients: When, for Whom, and How?
The significant mortality rate and prolonged ventilator days associated with invasive mechanical ventilation (IMV) in patients with severe COVID-19 have incited a debate surrounding the use of noninvasive respiratory support... read more
WHO Recommends Two New Drugs for COVID-19 Treatment
WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be. The... read more
Remdesivir Treatment for Hospitalized COVID-19 Patients in Canada
Remdesivir, when compared with standard of care, has a modest but significant effect on outcomes important to patients and health systems, such as the need for mechanical ventilation. Across 52 Canadian hospitals, we randomized... read more
Study Supports Remdesivir Treatment for COVID-19 Patients on Low-Flow Oxygen or No Oxygen
Remdesivir treatment increased the likelihood of clinical improvement in COVID-19 patients on low-flow oxygen or no oxygen, according to a new study by the Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg... read more
Efficacy of Inhaled Ciclesonide for Outpatient Treatment with Symptomatic COVID-19
The results of this randomized clinical trial demonstrated that ciclesonide did not achieve the primary efficacy end point of reduced time to alleviation of all COVID-19–related symptoms. A total of 413 participants... read more
1-year Mortality After COVID-19 ICU Admission
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes severe disease in some patients. Patients can experience severe disabilities after intensive care unit (ICU) admission due to coronavirus disease... read more
Post-acute Neurological Consequences of COVID-19
COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity. Our world has witnessed over 275 million confirmed cases of COVID-19... read more
Immunological Dysfunction Persists for 8 months Following Initial Mild-to-Moderate COVID-19 Infection
A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we studied individuals with LC compared to... read more
Effect of Early Fluvoxamine Treatment Among COVID-19 Patients
Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19 reduced the need for hospitalisation defined as retention in a COVID-19 emergency setting or transfer to... read more
Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients
Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo. A... read more
